Please assess the completion status of the following clinical trial:

Trial Title: The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 - 79~* Women of child bearing potential using a medically acceptable method of birth control (oral/transdermal/vaginal hormonal contraception, depo-provera injection, IUD, condom with spermicide, progestin implant, tubal ligation, oophorectomy, TAH) or abstinence.~* Capacity for giving written consent~* Diagnosis of PAD by:~  * previous angiogram (\>0.5 stenosis of a peripheral artery)~ * ankle-brachial index (ABI) of systolic pressure \<0.80~ * previous peripheral revascularization~* Smokers who smoke \< 10 cigarettes / day~Exclusion Criteria:~* Female subjects who are pregnant or nursing a child.~* Prior bleeding event related to drug therapy~* History of gastrointestinal ulceration~* History of known dipyridamole and/or aspirin allergy or intolerance~* History of coagulation, bleeding or blood disorders.~* Recent history of myocardial infarction or stroke in the previous 6 months~* Resting blood pressure of \<110mmHg systolic or \<60mmHg diastolic or of \>165mmHg systolic or \>95mmHg diastolic~* Patients with active infection as documented by abnormal laboratory tests at screen~* Concomitant serious illness, such as cancer, as per the principal investigator's discretion~* Current use of steroids for a chronic disease process~* Presence of ischemic leg ulcers~* History of contact allergies to the metal leads of the NIRS~* History of drug or alcohol abuse within the last 6 months.~* Subject who has received an experimental drug and/or used an experimental device within 30 days of screening.~* Subject who has donated ≥ one pint of blood within 8 weeks prior to screen.~* Use of aspirin for 2 weeks prior to the study~* Use of any other NSAID or COX-inhibitor for one week prior to the start of the study~* Use of any antioxidant vitamin for 2 weeks prior to the start of the study~* Use of plavix, pletal or trental for one week prior to the start of the study~* Use of acetaminophen for one week prior to each study visit~* Use of alcohol, caffeine or high fat foods for 24 hours prior to each study visit~* Has smoked any cigarettes for 24 hours prior to each study visit~* Platelet aggregation blood test less than 60 percent at Visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Dipyridamole 200mg and Aspirin 25mg bid (Type: ACTIVE_COMPARATOR): All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
- Dipyridamole 200 mg bid (Type: ACTIVE_COMPARATOR): All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
- Aspirin 25 mg bid (Type: ACTIVE_COMPARATOR): All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy (NIRS) of the legs.

Based on this trial design, predict the completion outcome and termination type (if applicable).